Clinical Guidelines for ST Analysis

The STAN system is based on a combination of FHR interpretation and ST Analysis, where both parts are of equal importance. The FHR must be correctly interpreted and set in relation to the ST Analysis in order to determine the recommended clinical actions.

Clinical guidelines have been developed and validated in clinical trials in order to facilitate clinical implementation of ST Analysis. The first guidelines were validated during the Swedish Randomized Controlled Trial involving almost 5,000 patients and have been in use in Europe since the introduction of ST Analysis in 2000. The guidelines available here were developed to reflect American nomenclature and clinical practice, and were validated in a clinical use study in 2005, involving over 500 patients.

Clinical Guidelines CLD300203/1 R1B, see here.

ST Analysis is indicated as an adjunct to FHR monitoring to determine whether obstetrical intervention is warranted when there is increased risk of developing metabolic acidosis. The intended use is in patients with planned vaginal delivery, a term pregnancy of 36 or more completed gestational weeks, singleton fetus, vertex presentation and ruptured amniotic membranes.

For a complete list of the indications, contraindications, warnings and precautions, see here.